ImmunityBio Announces Full Accrual of First Two Phases of Cancer Vaccine Trial in Participants with Lynch Syndrome and Initiation of Randomized Controlled Phase of the Trial

The first 20 participants have been enrolled in an important national, multicenter trial to test whether ImmunityBio’s Nant Cancer Vaccine comprising a tri-valent Adenovirus in combination with...

Related Keywords

United States ,American ,Americans ,Asad Umar ,Immunitybio Tri ,National Institutes Of Health ,Division Of Cancer Prevention ,Exchange Commission ,Company Form ,American Society Of Clinical Oncology ,Health Authority ,National Cancer Institute ,Translational Research ,National Institutes ,Patrick Soon Shiong ,Executive Chairman ,Global Chief Scientific ,Medical Officer ,Lynch Syndrome ,Cancer Prevention ,Clinical Oncology ,Private Securities Litigation Reform Act ,Markets ,